U.S., June 10 -- ClinicalTrials.gov registry received information related to the study (NCT07637292) titled 'Use of Dupilumab in Asthma in Real-world Setting' on June 04.
Brief Summary: The main objective of asthma pharmacological management in adults and teenagers is to maintain long-term control of the disease, including symptom relief, the prevention of exacerbations, the improvement of pulmonary function, the reduction of limitations in daily life and side effects of pharmacological treatments.
Dupilumab is a recombinant human monoclonal antibody that inhibits signalling of both IL-4 and IL-13, two Type 2 cytokines involved in inflammatory pathway. Dupixent obtained a European Marketing Authorization in September 2017 and was reimburs...